A commentary by Daryl Gohl was published in this month’s Nature Biotechnology. We had the opportunity to sit down with Dr. Gohl and discuss the these recent efforts to characterize variability in microbiome profiling methods and the importance of defined reference materials for assessing reproducibility. 1. What is the overriding message from
Kaleido Biosciences and CoreBiome Partner to Accelerate Microbiome Therapeutic Development – Agreement will increase productivity and speed of Kaleido’s clinical development programs BEDFORD, Mass, October 10, 2017 — Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced an agreement with CoreBiome, a genomics
CoreBiome recently closed a seed round of $800k, led by prominent Minneapolis-based angel investment group Gopher Angels, the University of Minnesota’s Discovery Capital fund, and Minnesota-based microbial standards company Microbiologics. The round also included several private investors.
CoreBiome has licensed a combination of patent-pending genomic technology and informatics tools from the University of Minnesota. These proprietary tools and techniques will allow CoreBiome to provide an unprecedented level of control, reproducibility, and accuracy in microbiome profiling.
Dan Knights, PhD (CEO, Co-Founder, and Chief Data Scientist) has been named among Twin Cities Business Magazine’s “Top 100 People to Know in Minnesota” for 2016. Knights, also an Assistant Professor in the University of Minnesota’s Computer Science and Engineering Department, is garnering national attention for his research combining medical inquiry
Founders Daryl Gohl, Dan Knights, and Kenneth Beckman collaborated with multiple colleagues in the microbiome field on an interdisciplinary project advancing the accuracy of microbiome studies. Their work was published in Nature Biotechnology. These experiments, conducted through the University of Minnesota Genomics Center (UMGC), examined sources of error and bias in
Micrometer Genomics, comprised of CoreBiome founders Kenneth Beckman, Daryl Gohl, and Dan Knights prior to their company name change, win the Mayo Clinic’s 2016 Walleye Tank pitch competition. The competition is Rochester’s first Biotech Business Pitch Competition, and was a completely sold-out, packed-house endeavor in it’s first edition this
The White House Office of Science and Technology Policy (OSTP), in collaboration with Federal agencies and private-sector stakeholders, announced the National Microbiome Initiative (NMI) on May 13, 2016. The NMI has been put in place with the eventual goal of applying advances in the microbiome field to areas such
Founder Dan Knights publishes a paper through the Federation of European Microbiological Sciences (FEMS) introducing machine learning to the microbiome field. Advances in DNA sequencing technology now allow for the collection and distribution of multi-faceted big data. Consequently, there is an increased need for improved methods of computational analysis in order
Founder Dan Knights shares his perspective on the future of microbiome research methods in an article published by Cell Host & Microbe. With a focus on predictive features, Knights believes the key to harnessing the human microbiome lies in computational advances in machine learning. Although advanced technologies capture detailed